Replimune Group, Inc. (REPL)
12.92
-0.32
(-2.42%)
USD |
NASDAQ |
Sep 11, 16:00
12.94
+0.02
(+0.12%)
After-Hours: 20:00
Replimune Group Enterprise Value : 1.002B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 1.002B |
| September 10, 2026 | 1.029B |
| September 09, 2026 | 1.130B |
| September 08, 2026 | 1.157B |
| September 04, 2026 | 1.180B |
| September 03, 2026 | 1.201B |
| September 02, 2026 | 1.259B |
| September 01, 2026 | 1.233B |
| August 31, 2026 | 1.202B |
| August 28, 2026 | 1.218B |
| August 27, 2026 | 1.227B |
| August 26, 2026 | 1.250B |
| August 25, 2026 | 1.244B |
| August 24, 2026 | 1.152B |
| August 21, 2026 | 1.157B |
| August 20, 2026 | 1.097B |
| August 19, 2026 | 1.160B |
| August 18, 2026 | 1.225B |
| August 17, 2026 | 1.145B |
| August 14, 2026 | 1.174B |
| August 13, 2026 | 1.192B |
| August 12, 2026 | 1.196B |
| August 11, 2026 | 1.063B |
| August 10, 2026 | 1.065B |
| August 07, 2026 | 929.44M |
| Date | Value |
|---|---|
| August 06, 2026 | 996.62M |
| August 05, 2026 | 910.12M |
| August 04, 2026 | 917.68M |
| August 03, 2026 | 916.84M |
| July 31, 2026 | 857.22M |
| July 30, 2026 | 370.98M |
| July 29, 2026 | 370.98M |
| July 28, 2026 | 365.94M |
| July 27, 2026 | 641.39M |
| July 24, 2026 | 731.25M |
| July 23, 2026 | 795.07M |
| July 22, 2026 | 819.43M |
| July 21, 2026 | 840.42M |
| July 20, 2026 | 799.27M |
| July 17, 2026 | 775.76M |
| July 16, 2026 | 716.13M |
| July 15, 2026 | 729.57M |
| July 14, 2026 | 745.52M |
| July 13, 2026 | 750.98M |
| July 10, 2026 | 839.58M |
| July 09, 2026 | 849.66M |
| July 08, 2026 | 850.50M |
| July 07, 2026 | 883.25M |
| July 06, 2026 | 879.89M |
| July 02, 2026 | 889.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 53.59B |
| Kalaris Therapeutics, Inc. | -11.68M |
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.77M |
| Total Expenses (Quarterly) | 69.77M |
| EPS Diluted (Quarterly) | -0.7202 |
| Earnings Yield | -25.38% |
| Normalized Earnings Yield | -25.38 |